
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Lonza Small Molecules is focused on leveraging its technologies and expertise to address solubility challenges and support drug development programs through commercialization.






